人类结核疫苗市场：按类型、按年龄层、按分销管道、按地区

2024年人类结核疫苗市场估计为6,420万美元，预计到2031年将达到9,510万美元，2024年至2031年的复合年增长率为5.8%。

图：2024 年按地区分類的人类结核疫苗市场占有率（%）

儘管结核病是一种可治癒和可预防的疾病，但它仍然是全球十大死亡原因之一。目前，唯一广泛使用的结核病疫苗是卡介苗（BCG）疫苗，其保护作用有限，仅建议儿童使用。迫切需要开发新的有效疫苗来遏制全球结核病负担。几种候选疫苗正在进行针对结核分枝桿菌生命週期不同阶段的临床试验。一种能够针对肺结核的发展和传播提供持久保护的疫苗可能会改变消除这种古老病原体的努力。

市场动态：

全球人类结核病疫苗市场主要是由全球结核病的持续负担所推动的。 2024年10月29日 根据世界卫生组织的数据，2023年总合125万人死于结核病。结核病在被冠状病毒感染疾病(COVID-19) 取代三年后，重新成为世界第一大死因，可能是由单一感染疾病引起的。改善诊断和疫苗的需求促使国际卫生组织大力投资结核病疫苗的研发。超过 15 种候选疫苗目前正处于不同阶段的临床试验。然而，高昂的开发成本和监管障碍带来了挑战。科学家正在探索新技术，例如 mRNA 平台，以提高结核疫苗生产的功效、安全性和简易性。由于印度和中国等国家的结核病发生率很高，亚太地区是最大的市场。开发有效的疫苗有可能遏制疾病传播，并为负担过重的医疗系统节省大量资金。

本研究的主要特点

本报告对全球人类结核疫苗市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模和年复合成长率（CAGR%）。

它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。

根据公司亮点、产品系列、主要亮点、绩效和策略等参数，包括全球人类结核疫苗市场的主要企业概况。

本研究涵盖的主要企业包括 GSK plc.、Serum Institute of India Pvt.、AJ Vaccines A/S、Taj Pharmaceuticals Ltd.、Merck &Co., Inc.、Bharat Biotech、Moderna、 Inc.、BioNTech SE 等

该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。

全球人类结核疫苗市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。

透过用于分析全球人类结核疫苗市场的各种策略矩阵，将有助于相关人员做出决策。

目录

第一章 研究目的与前提

• 研究目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要

第三章 市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 主要亮点
• 监管场景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景
• 流行病学

第四章 2019-2031 年人类结核疫苗市场（按类型）

• 减毒活疫苗
• 惰性
• 其他的

第五章 2019-2031 年人类结核疫苗市场，依年龄层划分

• 儿科的
• 成人

第六章 人类结核疫苗市场，依通路，2019-2031

• 私人的
• 公共

第七章 2019-2031 年人类结核疫苗市场（按地区）

• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第八章 竞争格局

• GSK plc.
• Serum Institute of India Pvt. Ltd.
• Valneva SE
• Archivel Farma
• BIOFABRI（Zendal）
• Japan BCG Laboratory
• CSL Seqirus
• GreenSignal Bio Pharma Private Limited（GSBPL）
• AJ Vaccines A/S
• Taj Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Bharat Biotech
• Moderna, Inc.
• BioNTech SE

第九章 分析师建议

• 命运之轮
• 分析师观点
• 一致的机会图

第10章 参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

The human tuberculosis vaccine market is estimated to be valued at USD 64.2 Mn in 2024 and is expected to reach USD 95.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.8% from 2024 to 2031.

Figure. Human Tuberculosis Vaccine Market Share (%), By Region, 2024

Tuberculosis remains one of the top 10 causes of death worldwide, despite being a curable and preventable disease. Currently, the only widely used TB vaccine is the Bacille Calmette-Guerin (BCG) vaccine, which provides limited protection and is only recommended for children. There is an urgent need for new, effective vaccines to control the global TB burden. Several candidate vaccines are in clinical trials, targeting different stages of the Mycobacterium tuberculosis lifecycle. Vaccines that provide lasting protection against pulmonary TB disease and transmission could be a game changer in the effort to eliminate this ancient pathogen.

Market Dynamics:

The global human tuberculosis vaccine market is primarily driven by the persistent burden of TB disease worldwide. On October 29, 2024, according to the WHO, a total of 1.25 million people died from tuberculosis (TB) in 2023. Worldwide, TB has probably returned to being the world's leading cause of death from a single infectious agent, following three years in which it was replaced by coronavirus disease (COVID-19). The need for improved diagnostics and vaccines has spurred heavy investments from global health organizations into TB vaccine R&D. Over 15 vaccine candidates are currently in clinical trials of different phases. However, high development costs and regulatory hurdles pose challenges. Scientists are exploring new technologies like mRNA platforms to improve the efficacy, safety, and ease of manufacture of tuberculosis vaccines. Asia Pacific is the largest market due to high TB prevalence in countries like India and China. Developing an effective vaccine could potentially curb disease transmission and generate substantial savings for overburdened healthcare systems.

Key Features of the Study:

This report provides in-depth analysis of the global human tuberculosis vaccine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global human tuberculosis vaccine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include GSK plc., Serum Institute of India Pvt. Ltd., Valneva SE, Archivel Farma, BIOFABRI (Zendal), Japan BCG Laboratory, CSL Seqirus, GreenSignal Bio Pharma Private Limited (GSBPL), AJ Vaccines A/S, Taj Pharmaceuticals Ltd., Merck & Co., Inc., Bharat Biotech, Moderna, Inc., and BioNTech SE

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global human tuberculosis vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human tuberculosis vaccine market

Market Segmentation

• By Type Insights (Revenue, USD Mn, 2019 - 2031)
  • Live attenuated vaccine
  • Inactivated
  • Others
• By Age Group Insights (Revenue, USD Mn, 2019 - 2031)
  • Pediatrics
  • Adults
• By Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
  • Private
  • Public
• By Regional Insights (Revenue, USD Mn, 2019 - 2031)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • GSK plc.
  • Serum Institute of India Pvt. Ltd.
  • Valneva SE
  • Archivel Farma
  • BIOFABRI (Zendal)
  • Japan BCG Laboratory
  • CSL Seqirus
  • GreenSignal Bio Pharma Private Limited (GSBPL)
  • AJ Vaccines A/S
  • Taj Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Bharat Biotech
  • Moderna, Inc.
  • BioNTech SE

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Human Tuberculosis Vaccine Market, By Type
  • Human Tuberculosis Vaccine Market, By Age Group
  • Human Tuberculosis Vaccine Market, By Distribution Channel
  • Human Tuberculosis Vaccine Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology

4. Human Tuberculosis Vaccine Market, By Type, 2019-2031, (USD Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Live attenuated vaccine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Inactivated
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

5. Human Tuberculosis Vaccine Market, By Age Group, 2019-2031, (USD Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Pediatrics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Human Tuberculosis Vaccine Market, By Distribution Channel, 2019-2031, (USD Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020- 2031
  • Segment Trends
• Private
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Public
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Human Tuberculosis Vaccine Market, By Region, 2019 - 2031, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
  • Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Serum Institute of India Pvt. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Valneva SE
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Archivel Farma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BIOFABRI (Zendal)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Japan BCG Laboratory
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• CSL Seqirus
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GreenSignal Bio Pharma Private Limited (GSBPL)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AJ Vaccines A/S
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Taj Pharmaceuticals Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bharat Biotech
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Moderna, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BioNTech SE
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us